← Leaderboards
Mark W Grinstaff
Boston University (Charles River Campus)
$24,362,733
Attributed
$47,549,791
Total exposure
31
Grants
24
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$47,549,791 · 31
By mechanism
R01$37,410,492 · 21
T32$3,874,975 · 1
R21$3,149,212 · 7
U01$2,539,139 · 1
R56$575,973 · 1
Top collaborators
- Yolonda L Colson37 shared
- Ara Nazarian15 shared
- Orian S Shirihai11 shared
- Andrew Kruse8 shared
- Chandrajit Premanand Raut8 shared
- Brian D Snyder8 shared
- Edward Kenneth Rodriguez7 shared
- Arturo Vegas6 shared
Most similar at Boston University (Charles River Campus)
Same institution · by research overlap
- Yolonda L Colson$10,834,927
- Orian S Shirihai$11,530,700
- Danielle Fitzgerald$89,896
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoPolymersIn VitroTissuesPropertyPreventBaseStructureOperative Surgical ProceduresDesignExperimental DesignsCollaborationsInnovationBiocompatible MaterialsToxic EffectAnimalsCytotoxicityExperimental StudyCellsSurfaceSiteProteinsDosePharmaceutical Preparations
Grant awards (121)
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas$712,043
R01 · FY2025 · CA
A self-amplifying RNA-based synthetic nanobody platform for next-generation therapeutics$651,384
R01 · FY2025 · EB
Sulfated Poly-Amido-Saccharide (sulPAS) Biomaterials as Anticoagulants$639,742
R01 · FY2025 · HL · contact PI
Modified saRNA Encoded BiTEs for Lung Cancer$635,248
R01 · FY2025 · CA · contact PI
The Conundrum of Absentee Receptors: Efficacy Potentiation Through Drug-Receptor Modulation$629,586
R01 · FY2025 · AR · contact PI
Lysosomal Regeneration (LysoGen) and Rescue as a Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)$619,776
R01 · FY2025 · DK · contact PI
Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder$601,723
R01 · FY2025 · AR · contact PI
Biodegradable, Biocompatible Pressure Sensitive Adhesives$594,799
R01 · FY2025 · HL · contact PI
A Relaxin-loaded Hydrogel for the Treatment of Hypertrophic Scars$486,042
R01 · FY2025 · AR · contact PI
Precise tumor targeting with logic CAR circuits$323,559
U01 · FY2025 · CA
Translational Research in Biomaterials$252,674
T32 · FY2025 · EB · contact PI
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas$676,443
R01 · FY2024 · CA
Lysosomal Regeneration (LysoGen) and Rescue as a Treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)$642,653
R01 · FY2024 · DK · contact PI
The Conundrum of Absentee Receptors: Efficacy Potentiation Through Drug-Receptor Modulation$628,970
R01 · FY2024 · AR · contact PI
Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder$603,668
R01 · FY2024 · AR · contact PI
Sulfated Poly-Amido-Saccharide (sulPAS) Biomaterials as Anticoagulants$551,239
R01 · FY2024 · HL · contact PI
Biodegradable, Biocompatible Pressure Sensitive Adhesives$545,646
R01 · FY2024 · HL · contact PI
A Relaxin-loaded Hydrogel for the Treatment of Hypertrophic Scars$526,041
R01 · FY2024 · AR · contact PI
Precise tumor targeting with logic CAR circuits$525,026
U01 · FY2024 · CA
Translational Research in Biomaterials$305,480
T32 · FY2024 · EB · contact PI
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas$695,566
R01 · FY2023 · CA
The Conundrum of Absentee Receptors: Efficacy Potentiation Through Drug-Receptor Modulation$652,797
R01 · FY2023 · AR · contact PI
Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder$625,269
R01 · FY2023 · AR · contact PI
Sulfated Poly-Amido-Saccharide (sulPAS) Biomaterials as Anticoagulants$562,489
R01 · FY2023 · HL · contact PI
Precise tumor targeting with logic CAR circuits$553,669
U01 · FY2023 · CA
Biodegradable, Biocompatible Pressure Sensitive Adhesives$520,496
R01 · FY2023 · HL · contact PI
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNGTUMOR RECURRENCE$505,038
R01 · FY2023 · CA · contact PI
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADINGFOR TREATING MESOTHELIOMA$500,083
R01 · FY2023 · CA · contact PI
R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma$226,784
R21 · FY2023 · CA · contact PI
Translational Research in Biomaterials$223,673
T32 · FY2023 · EB · contact PI
Translational Research in Biomaterials$53,810
T32 · FY2023 · EB · contact PI
Supratherapeutic PTX Buttresses Reduce Locoregional Recurrence Rates Following Surgery for Soft Tissue Sarcomas$749,261
R01 · FY2022 · CA
The Conundrum of Absentee Receptors: Efficacy Potentiation Through Drug-Receptor Modulation$649,942
R01 · FY2022 · AR · contact PI
Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder$621,398
R01 · FY2022 · AR · contact PI
Biodegradable, Biocompatible Pressure Sensitive Adhesives$555,638
R01 · FY2022 · HL · contact PI
Precise tumor targeting with logic CAR circuits$554,582
U01 · FY2022 · CA
Sulfated Poly-Amido-Saccharide (sulPAS) Biomaterials as Anticoagulants$553,824
R01 · FY2022 · HL · contact PI
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADINGFOR TREATING MESOTHELIOMA$539,833
R01 · FY2022 · CA · contact PI
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNGTUMOR RECURRENCE$468,259
R01 · FY2022 · CA · contact PI
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE$452,836
R01 · FY2022 · CA · contact PI
Translational Research in Biomaterials$318,373
T32 · FY2022 · EB · contact PI
R21: A novel antibody-drug conjugate for treatment of squamous cell lung carcinoma$192,844
R21 · FY2022 · CA · contact PI
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE$610,821
R01 · FY2021 · CA · contact PI
Precise tumor targeting with logic CAR circuits$582,303
U01 · FY2021 · CA
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADING FOR TREATING MESOTHELIOMA$568,654
R01 · FY2021 · CA · contact PI
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNG TUMOR RECURRENCE$437,722
R01 · FY2021 · CA · contact PI
Translational Research in Biomaterials$199,696
T32 · FY2021 · EB · contact PI
Relaxin-2 as a Novel Protein Therapeutic for the Treatment of Shoulder Arthrofibrosis$575,973
R56 · FY2020 · AR · contact PI
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADING FOR TREATING MESOTHELIOMA$569,979
R01 · FY2020 · CA · contact PI
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE$526,098
R01 · FY2020 · CA · contact PI
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNG TUMOR RECURRENCE$439,002
R01 · FY2020 · CA · contact PI
Multi-functional targeted bio-conjugate platform to dismantle neutrophil extracellular traps (NETs)$247,500
R21 · FY2020 · HL · contact PI
A novel approach for reversal of autophagic defects using lysosome-targeted nanoparticles$200,625
R21 · FY2020 · AG
R21: Acidic Nanoparticles for Restoration of Autophagy in Age-associated NAFLD$200,625
R21 · FY2020 · AG · contact PI
Translational Research in Biomaterials$197,466
T32 · FY2020 · EB · contact PI
OPTIMIZATION OF NANOPARTICLE TUMOR-LOCALIZATION AND DRUG-LOADING FOR TREATING MESOTHELIOMA$534,718
R01 · FY2019 · CA · contact PI
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE$489,515
R01 · FY2019 · CA · contact PI
Efficacy and Safety of a Novel, Implantable Drug-eluting Film in Sarcoma$404,583
R01 · FY2019 · EB
Dissolvable Hydrogel Dressing for the Treatment of Burns$381,780
R01 · FY2019 · EB · contact PI
SUPERHYDROPHOBIC DRUG LOADED BUTTRESSES FOR PREVENTION OF LUNG TUMOR RECURRENCE$355,982
R01 · FY2019 · CA · contact PI
Translational Research in Biomaterials$292,124
T32 · FY2019 · EB · contact PI
R21: Acidic Nanoparticles for Restoration of Autophagy in Age-associated NAFLD$257,000
R21 · FY2019 · AG · contact PI
A novel approach for reversal of autophagic defects using lysosome-targeted nanoparticles$254,750
R21 · FY2019 · AG
Multi-functional targeted bio-conjugate platform to dismantle neutrophil extracellular traps (NETs)$206,250
R21 · FY2019 · HL · contact PI
TUMOR SPECIFIC DELIVERY OF VERTICILLIN A OVERCOMES EPIGENETIC SILENCING RESPONSIBLE FOR DRUG RESISTANCE$608,862
R01 · FY2018 · CA · contact PI
Efficacy and Safety of a Novel, Implantable Drug-eluting Film in Sarcoma$421,129
R01 · FY2018 · EB
Dissolvable Hydrogel Dressing for the Treatment of Burns$381,569
R01 · FY2018 · EB · contact PI
Translational Research in Biomaterials$287,316
T32 · FY2018 · EB · contact PI
Translational Research in Biomaterials$95,772
T32 · FY2018 · EB · contact PI
Efficacy and Safety of a Novel, Implantable Drug-eluting Film in Sarcoma$407,644
R01 · FY2017 · EB
Dissolvable Hydrogel Dressing for the Treatment of Burns$379,126
R01 · FY2017 · EB · contact PI
Synthesis, Characterization, and Evaluation of Polymeric Tissue Lubricants$369,204
R01 · FY2017 · AR · contact PI
Translational Research in Biomaterials$261,914
T32 · FY2017 · EB · contact PI
Efficacy and Safety of a Novel, Implantable Drug-eluting Film in Sarcoma$430,368
R01 · FY2016 · EB
Dissolvable Hydrogel Dressing for the Treatment of Burns$391,814
R01 · FY2016 · EB · contact PI
Synthesis, Characterization, and Evaluation of Polymeric Tissue Lubricants$367,218
R01 · FY2016 · AR · contact PI
Translational Research in Biomaterials$281,172
T32 · FY2016 · EB · contact PI
Synthesis, Characterization, and Evaluation of Polymeric Tissue Lubricants$364,672
R01 · FY2015 · AR · contact PI
Characterizing electrostatic interactions between glycosaminoglycans and cationic$274,341
R01 · FY2015 · GM · contact PI
Translational Research in Biomaterials$249,608
T32 · FY2015 · EB · contact PI
Synthesis, Characterization, and Evaluation of Polymeric Tissue Lubricants$380,597
R01 · FY2014 · AR · contact PI
Flexible, Conformal, Polymeric Films for Lung Resection Margins$336,653
R01 · FY2014 · CA · contact PI
Characterizing electrostatic interactions between glycosaminoglycans and cationic$286,765
R01 · FY2014 · GM · contact PI
Tunable Nanofiber Mesh Coatings for Improved Nanopores Sensing$198,486
R21 · FY2014 · EB
Flexible, Conformal, Polymeric Films for Lung Resection Margins$326,094
R01 · FY2013 · CA · contact PI
Characterizing electrostatic interactions between glycosaminoglycans and cationic$300,144
R01 · FY2013 · GM · contact PI
Tunable Nanofiber Mesh Coatings for Improved Nanopores Sensing$245,550
R21 · FY2013 · EB
A Portable Wound Hemostasis System Using a Hydrogel Polymeric Foam$224,130
R21 · FY2013 · EB
Translational Research in Biomaterials$160,495
T32 · FY2013 · EB · contact PI
Flexible, Conformal, Polymeric Films for Lung Resection Margins$345,579
R01 · FY2012 · CA · contact PI
Characterizing electrostatic interactions between glycosaminoglycans and cationic$269,789
R01 · FY2012 · GM · contact PI
A Portable Wound Hemostasis System Using a Hydrogel Polymeric Foam$207,168
R21 · FY2012 · EB
Translational Research in Biomaterials$169,372
T32 · FY2012 · EB · contact PI
Bacteriophobic Coatings for Inhibition of Pathogenic Biofilms$558,035
R01 · FY2011 · AR · contact PI
Flexible, Conformal, Polymeric Films for Lung Resection Margins$361,745
R01 · FY2011 · CA · contact PI
Translational Research in Biomaterials$169,368
T32 · FY2011 · EB · contact PI
Bacteriophobic Coatings for Inhibition of Pathogenic Biofilms$572,402
R01 · FY2010 · AR · contact PI
Translational Research in Biomaterials$177,962
T32 · FY2010 · EB · contact PI
Bacteriophobic Coatings for Inhibition of Pathogenic Biofilms$384,959
R01 · FY2009 · AR · contact PI
Reversing Electrostatic Interactions for Improved Gene Delivery$335,665
R01 · FY2009 · EB · contact PI
Translational Research in Biomaterials$178,700
T32 · FY2009 · EB · contact PI
Bacteriophobic Coatings for Inhibition of Pathogenic Biofilms$166,556
R01 · FY2009 · AR · contact PI
Nanoscale Functional Dendrimer-DNA Assemblies$162,500
R21 · FY2009 · CA · contact PI
Bacteriophobic Coatings for Inhibition of Pathogenic Biofilms$415,889
R01 · FY2008 · AR · contact PI
Reversing Electrostatic Interactions for Improved Gene Delivery$336,476
R01 · FY2008 · EB · contact PI
Ophthalmic Sealants II: Dendritic Biomaterials for Repair of Occular Wounds$190,317
R01 · FY2008 · EY · contact PI
Nanoscale Functional Dendrimer-DNA Assemblies$162,500
R21 · FY2008 · CA · contact PI
Reversing Electrostatic Interactions for Improved Gene Delivery$348,583
R01 · FY2007 · EB · contact PI
Ophthalmic Sealants II: Dendritic Biomaterials for Repair of Occular Wounds$194,201
R01 · FY2007 · EY · contact PI
Nanoscale Functional Dendrimer-DNA Assemblies$162,500
R21 · FY2007 · CA · contact PI
Reversing Electrostatic Interactions for Improved Gene Delivery$359,775
R01 · FY2006 · EB · contact PI
Interfacial Biomaterials$346,294
R01 · FY2006 · EB · contact PI
Ophthalmic Sealants II: Dendritic Biomaterials for Repair of Occular Wounds$200,000
R01 · FY2006 · EY · contact PI
Interfacial Biomaterials$329,115
R01 · FY2005 · EB
New Biomaterials for Sutureless Ophthalmic Surgeries$313,650
R01 · FY2005 · EY
New Biomaterials for Sutureless Ophthalmic Surgeries$323,000
R01 · FY2004 · EY
Interfacial Biomaterials$319,903
R01 · FY2004 · EB
Interfacial Biomaterials$341,273
R01 · FY2003 · EB
New Biomaterials for Sutureless Ophthalmic Surgeries$259,311
R01 · FY2003 · EY
New Biomaterials for Sutureless Ophthalmic Surgeries$48,689
R01 · FY2003 · EY
New Biomaterials for Sutureless Ophthalmic Surgeries$346,500
R01 · FY2002 · EY